AstraZeneca Stock Leads 3 Cash Flow Picks Trading Below Fair Value

With inflation pressures, volatile energy markets and mixed economic signals shaping headlines, many investors are looking for opportunities where prices do not fully reflect underlying cash generation. The Undervalued Stocks Based On Cash Flows screener focuses on companies that SWS DCF valuation suggests are trading below their estimated fair value, based on future cash flow potential. That can be appealing if you care more about what a business can earn over time than about short term market swings. In this article, you will see 3 stocks from this screener that stand out on cash flows and valuation grounds.

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical company based in Cambridge that discovers, develops, manufactures, and sells prescription medicines across cancer, cardiovascular, metabolic, respiratory, vaccine, immune and rare disease treatments, working with doctors and health systems worldwide.

Operations: AstraZeneca generates around US$60.4b in revenue primarily from its pharmaceuticals portfolio.

Market Cap: £196.5b

Investors looking at AstraZeneca are getting a large, diversified pharmaceuticals company with a deep late stage pipeline in oncology and other high medical need areas, backed by profitability metrics like a 21.9% ROE and a history of strong earnings growth. At the same time, Simply Wall St’s cash flow model suggests the stock trades materially below its estimated fair value, while analysts see scope for higher earnings over time. Together, these factors make the valuation story notable. On the other hand, there is meaningful reliance on a handful of blockbuster drugs, high R&D spending and a sizeable debt load, plus growing pricing pressure and biosimilar competition, all of which investors need to weigh carefully against the potential rewards.

AstraZeneca’s cash flow profile and 21.9% ROE suggest the current pricing may be missing something that is in plain sight. However, the real twist sits inside the DCF valuation analysis for AstraZeneca

Foresight Group Holdings (LSE:FSG)

Overview: Foresight Group Holdings is a London based asset manager that runs infrastructure, renewable energy, and private equity funds, giving institutional and retail investors access to real assets, sustainable investment strategies, and smaller company growth opportunities across the UK, Europe, and Australia.

Operations: Foresight Group Holdings generates about £114.8m of revenue from Real Assets and £50.1m from Private Equity, with most income tied to infrastructure and renewables focused mandates.

Market Cap: £525.3m

Foresight Group Holdings may appeal to investors who focus on fee based cash flows tied to long term themes such as energy transition and infrastructure, while also watching valuation closely. Revenue is £164.9m with net profit margins of 27.7%, supported by high reported returns on equity and an ongoing share buyback that reduces the share count. At the same time, the business is still concentrated in UK and European infrastructure and relies on performance fees and external borrowings, so profitability can come under pressure if fundraising, AUM growth, or policy support for renewables slow. The key question is how those growth ambitions, high margin products, and capital returns fit together in the overall picture that sits behind the current share price.

Foresight Group Holdings sits at the intersection of real assets, renewables and private equity, yet the real story may be how those fee streams and margins stack up against today’s share price. The full picture sits inside the DCF valuation analysis for Foresight Group Holdings

BAE Systems (LSE:BA.)

Overview: BAE Systems is a London based defense and aerospace company that supplies combat aircraft, naval ships, electronic warfare gear, munitions, and cyber security services to governments and defense agencies around the world.

Operations: BAE Systems generates most of its revenue from Electronic Systems (£7.5b), Air (£7.4b), Maritime (£6.6b), and Platforms & Services (£5.0b), with smaller contributions from Cyber & Intelligence (£2.4b) and Head Quarter (£52m), partly offset by intra group revenue.

Market Cap: £55.8b

For investors watching the Undervalued Stocks Based On Cash Flows screener, BAE Systems brings together a £75b order backlog, exposure to higher defense spending across NATO and Asia, and growing demand for areas such as drones, electronic warfare and precision munitions, while trading below Simply Wall St’s estimated fair value on cash flows. At the same time, earnings growth has been solid rather than spectacular, margins sit around 7.3%, and the business depends heavily on long term government contracts that can be affected by politics, supply chain issues and ESG pressure. How that mix of long term visibility, capacity expansion projects in the US and UK, and concentrated contract risk compares with today’s share price is a key consideration for investors.

BAE Systems looks like a case where a £75b backlog and long term defense trends may not fully line up with the current share price. See how the cash flows stack up in the DCF valuation analysis for BAE Systems

The three stocks in this article are only a starting point, as the full Undervalued Stocks Based On Cash Flows screen on Simply Wall St currently surfaces 40 more companies with equally compelling cash flow and valuation stories inside the Undervalued Stocks Based On Cash Flows screener. Use Simply Wall St to identify and analyze the specific cash flow catalysts, valuation gaps, and risk factors that matter to you, so you can focus on the highest conviction opportunities for your portfolio.

Take Control of Your Investment Journey

If AstraZeneca or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond These Picks?

Some of the most interesting breakout stories start flying before headlines catch up. Scan fresh ideas under the radar for now, while it matters, and consider getting in early.

• Consider potential income momentum by lining up companies screened as 4 dividend fortresses that aim to keep cash coming in even when prices are dropping elsewhere.
• Track where AI demand could be building by scanning infrastructure providers in the curated 55 AI infrastructure stocks before the crowd fully catches on.
• Evaluate possible robotics momentum by reviewing hand picked automation leaders inside the 34 robotics and automation stocks while they still sit largely under the radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com